Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader

27 Oct 2015

Wardell et al. investigated the efficacy of selective ER modulator/degrader hybrid, RAD1901, in modulating estrogen receptor activity. RAD1901 has the unique ability (within selective ER modulators) to enter the readily enter the brain, a common site of breast cancer metastasis, making it a potential candidate for targeted therapy for the treatment of breast cancer brain metastases.